Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy

Biomaterials

Volumn 59, Issue , 2015, Pages 88-101

  Satsangi, Arpan ^a,b   Roy, Sudipa S ^c   Satsangi, Rajiv K ^d   Tolcher, Anthony W ^e   Vadlamudi, Ratna K ^c   Goins, Beth ^a   Ong, Joo L ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b The University of Texas at San Antonio   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d Rann Research Corporation   (United States)

^e South Texas Accelerated Research Therapeutics (START)   (United States)

Author keywords

Breast cancer; Chemotherapy; Dendrimer; Drug delivery; Liposome; Nanoencapsulation; Nanoparticle; Sequential active targeting

Indexed keywords

BIOCHEMISTRY; CELLS; CHEMOTHERAPY; DENDRIMERS; DRUG DELIVERY; LIPOSOMES; NANOPARTICLES; TOXICITY; TUMORS;

ACTIVE TARGETING; BREAST CANCER; CANCER CELL TARGETING; EXPRESSION PROFILE; NANO-ENCAPSULATION; POLYAMIDOAMINE DENDRIMERS; SYSTEMIC TOXICITIES; TARGETED DRUG DELIVERY;

DISEASES;

CATHEPSIN B; FOLATE RECEPTOR; LIPOSOME; NANOCONJUGATE; PACLITAXEL; PACLITAXEL GLYCYLPHENYLALANYLLEUCYLGLYCINE POLYAMIDOAMINE DENDRIMER CONJUGATE; POLY(ETHYLENE GLYCOL)DISTEAROYLPHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NANOMATERIAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RETENTION; DRUG SELECTIVITY; DRUG SPECIFICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MOLECULARLY TARGETED THERAPY; MOUSE; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; PHOSPHOLIPID SYNTHESIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; DRUG DELIVERY SYSTEM; FEMALE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOSOMES; NANOSTRUCTURES; PACLITAXEL;

EID: 84930165069     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.03.039     Document Type: Article

References (54)

1. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] 2013, International Agency for Research on Cancer, Lyon, France, Available from: http://globocan.iarc.fr.
2. Bharali D.J., Khalil M., Gurbuz M., Simone T.M., Mousa S.A. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomed 2009, 4:1-7.
3. Piccart-Gebhart M.J., Burzykowski T., Buyse M., Sledge G., Carmichael J., Lück H.J., et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. JClin Oncol 2008, 26(12):1980-1986.
4. Fauzee N.J.S., Dong Z., Wang Y.L. Taxanes: promising anti-cancer drugs. Asian Pac J Cancer Prev 2011, 12:837-851.
5. Sparano J.A., Wang M., Martino S., Jones V., Perez E.A., Saphner T., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. NEngl J Med 2008, 358:1663-1671.
6. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
7. Holmes F.A., Walters R.S., Theriault R.L., Forman A.D., Newton L.K., Raber M.N., et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. JNatl Cancer Inst 1991, 83:1797-1805.
8. Squibb Bristol-Myers Taxol (paclitaxel) Injection (patient information included). Online 2013, Available from: URL: http://packageinserts.bms.com/pi/pi_taxol.pdf.
9. Merisko-Liversidge E., Sarpotdar P., Bruno J., Hajj S., Wei L., Peltier N., et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 1996, 13(2):272-278.
10. Constantinides P.P., Lambert K.J., Tustian A.K., Schneider B., Lalji S., Ma W., et al. Formulation development and antitumor activity of a filter sterilizable emulsion of paclitaxel. Pharm Res 2000, 17(2):175-182.
11. Wang T.H., Wang H.S., Soong Y.K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88(11):2619-2628.
12. Luo Y., Ziebell M.R., Prestwich G.D. Ahyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromol 2000, 1(2):208-218.
13. Gelderblom H., Verweij J., Nooter K., Sparreboom V., Cremophor E.L. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37:1590-1598.
14. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
15. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:705-763.
16. Tolcher A.W., Sugarman S., Gelmon K.A., Cohen R., Saleh M., Isaacs C., et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. JClin Oncol 1999, 17:478-484.
17. Faivre S., Djelloul S., Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006, 33:407-420.
18. Satsangi A., Roy S.S., Satsangi R.K., Vadlamudi R.K., Ong J.L. Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells. Mol Pharm 2014, 11(6):1906-1918.
19. Mufamadi M.S., Pillay V., Choonara Y.E., Du Toit L.C., Modi G., Naidoo D., et al. Areview on composite liposomal technologies for specialized drug delivery. JDrug Del 2011, 19. Article ID 939851.
20. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Del Rev 2013, 65:36-48.
21. Kim M.J., Lee H.J., Lee I.A., Kim I.Y., Lim S.K., Cho H.A., et al. Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes. Arch Pharm Res 2008, 31(4):539-546.
22. ElBayoumi T.A., Torchilin V.P. Tumor-targeted nanomedicines: enhanced antitumor efficacy invivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 2009, 15(6):1973-1980.
23. Yu M.K., Park J., Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012, 2(1):3-44.
24. Wu J., Liu Q., Lee R.J. Afolate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm 2006, 316(1):148-153.
25. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51(4):691-744.
26. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M.M., et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: invitro studies. Bioconjugate Chem 1999, 10:289-298.
27. Torchilin V., Weissig V. Chapter-1: Preparation of Liposomes. In 'Liposomes: A practical approach' 2003, 5. Oxford University Press.
28. Steward J.C. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980, 104:10-14.
29. Vadlamudi R.K., Wang R.A., Mazumdar A., Kim Y.S., Shin J., Sahin A., et al. Molecular cloning and characterization of pelp1, a novel human coregulator of estrogen receptor α. JBiol Chem 2001, 276:38272-38279.
30. Elliott E., Sloane B.F. The cysteine protease cathepsin B in cancer. Perspect Drug Discov Des 1996, 6:12-32.
31. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006, 6:764-775.
32. Garin-Chesa P., Campbell I., Saigo P.E., Lewis J.L., Old L.J., Rettig W.J. Trophoblast and ovarian cancer antigen LK26: sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Amer J Pathol 1993, 142:557-567.
33. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., Leamon C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005, 338:284-293.
34. Yoo H., Park T. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-peg-folate conjugate. JControl Rel 2004, 100:247-256.
35. Campbell I.G., Jones T., Trowsdale J. High affinity folate-binding protein is a marker for ovarian cancer. Cancer Res 1994, 51:5329-5338.
36. Mantovani L.T., Miotti S., Menard S. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by monoclonal antibodies Mov18 and Mov19. Eur J Cancer 1994, 30A:363-369.
37. Shiokawa T., Hattori Y., Kawano K., Ohguchi Y., Kawakami H., Toma K., et al. Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin a on targeting ability and antitumor effect invitro and invivo. Clin Cancer Res 2005, 11(15):2018-2025.
38. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006, 1:297-315.
39. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
40. Erhan Y., Özdemir N., Zekioglu O., Nart D., Ciris M. Breast carcinomas with choriocarcinomatous features: case reports and review of the literature. Breast J 2002, 8(4):244-248.
41. Filho O.G., Miiji L.N.O., Vainchenker M., Gordan Â.N. Breast cancer with choriocarcinomatous and neuroendocrine features. Sao Paulo Med J 2001, 119(4):154-155.
42. L'Azou B., Jorly J., On D., Sellier E., Moisan F., Fleury-Feith J., et al. Invitro effects of nanoparticles on renal cells. Part Fibre Toxicol 2008, 5:22.
43. Geng H., Lan R., Wang G., Siddiqi A.R., Naski M.C., Brooks A.I., et al. Inhibition of autoregulated TGF signaling simultaneously enhances proliferation and differentiation of kidney epithelium and promotes repair following renal ischemia. Amer J Pathol 2009, 174:1291-1308.
44. Lieberthal W., Zhang L., Patel V.A., Levine J.S. AMPK protects proximal tubular cells from stress-induced apoptosis by an ATP-independent mechanism: potential role of Akt activation. Amer J Physiol Ren Physiol 2011, 301:F1177-F1192.
45. Ryan M.J., Johnson G., Kirk J., Fuerstenberg S.M., Zager R.A., Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 1994, 45:48-57.
46. Yang T., Cui F.D., Choi M.K., Cho J.W., Chung S.J., Shim C.K., et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: Invitro and invivo evaluation. Int J Pharm 2007, 338(1):317-326.
47. Immordino M.L., Brusa P., Arpicco S., Stella B., Dosio F., Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. JControl Rel 2003, 91(3):417-429.
48. Paulos C.M., Reddy J.A., Leamon C.P., Turk M.J., Low P.S. Ligand binding and kinetics of folate receptor recycling invivo: impact on receptor-mediated drug delivery. Mol Pharmacol 2004, 66:1406-1414.
49. Lacroix M., Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004, 83(3):249-289.
50. Nakayama S., Torikoshi Y., Takahashi T., Yoshida T., Sudo T., Matsushima T., et al. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res 2009, 11:R12.
51. Lee J., Lilly G.D., Doty R.C., Podsiadlo P., Kotov N.A. Invitro toxicity testing of nanoparticles in 3D cell culture. Small 2009, 5(10):1213-1221.
52. Sayes C.M., Reed K.L., Warheit D.B. Assessing toxicity of fine and nanoparticles: comparing invitro measurements to invivo pulmonary toxicity profiles. Toxicol Sci 2007, 97(1):163-180.
53. Feng Y., Shen J., Streaker E.D., Lockwood M., Zhu Z., Low P.S., et al. Afolate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibodydependent cell-mediated cytotoxicity. Arthritis Res Ther 2011, 13:R59.
54. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. JLeukoc Biol 2009, 86:1065-1073.